Longeveron Inc. (LGVN)
NASDAQ: LGVN · Real-Time Price · USD
0.9600
+0.0723 (8.14%)
At close: Mar 17, 2026, 4:00 PM EDT
0.8800
-0.0800 (-8.33%)
After-hours: Mar 17, 2026, 7:59 PM EDT
Longeveron Employees
Longeveron had 25 employees as of December 31, 2024. The number of employees increased by 1 or 4.17% compared to the previous year.
Employees
25
Change (1Y)
1
Growth (1Y)
4.17%
Revenue / Employee
$57,480
Profits / Employee
-$853,640
Market Cap
22.34M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 25 | 1 | 4.17% | 25 | 0 |
| Dec 31, 2023 | 24 | 3 | 14.29% | 23 | 1 |
| Dec 31, 2022 | 21 | 1 | 5.00% | 19 | 2 |
| Dec 31, 2021 | 20 | 8 | 66.67% | 18 | 2 |
| Dec 31, 2020 | 12 | -4 | -25.00% | 12 | 0 |
| Sep 30, 2020 | 12 | -4 | -25.00% | 12 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Vistagen Therapeutics | 59 |
| Senti Biosciences | 34 |
| Passage Bio | 24 |
| Daré Bioscience | 23 |
| Skye Bioscience | 16 |
| VYNE Therapeutics | 10 |
| Neuphoria Therapeutics | 8 |
| NanoViricides | 7 |
LGVN News
- 8 hours ago - Longeveron Inc. (LGVN) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 11 hours ago - Longeveron Announces 2025 Full Year Financial Results and Provides Business Update - GlobeNewsWire
- 12 hours ago - Longeveron Braces For Q4 Results Following Recent Funding Boost - Benzinga
- 6 days ago - Longeveron Announces Closing of Private Placement of up to $30 Million - GlobeNewsWire
- 7 days ago - Longeveron (LGVN) Shares Surge On $30 Million Private Placement Deal - Benzinga
- 20 days ago - Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell - GlobeNewsWire
- 4 weeks ago - Longeveron® Appoints Stephen H. Willard as Chief Executive Officer - GlobeNewsWire
- 5 weeks ago - Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program - GlobeNewsWire